Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction. Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised RayzeBio on the deal. RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced a $160 million...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
